Veru’s Novel COVID-19 Drug Candidate Reduces Dea
Post# of 1418
(Total Views: 348)
Posted On: 04/11/2022 1:56:33 PM
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
April 11, 2022 06:30 ET
"Patients in both treatment groups were allowed to receive standard of care including remdesivir, dexamethasone , anti-IL6 receptor antibodies, and JAK inhibitors. "
Almost 1/2 the people died on the big boy drugs. Guess 'that stuff' isn't all what it's cracked up to be.
"The prespecified primary endpoint was death at or before day 60. Sabizabulin treatment resulted in a clinically and statistically meaningful 55% relative reduction in deaths (p=0.0029) in the intent to treat population. Placebo group (n=52) had a 45% mortality rate compared to the sabizabulin-treated group (n=98) which had a 20% mortality rate. The secondary efficacy endpoints are still being analyzed at the time of this release."
1 out of 5 died on Sabizabulin. I didn't look to see what happened after day 60.
If sabizabulin reduced deaths 55%, then maybe Todos could have wrote the PR, Tollovid reduced deaths 100%. What is interesting in the Todos trial is those patients that received SOC and a death rate of 22% COVID-related deaths in placebo group. The SOC placebo arm has a very similar death rate to those on sabizabulin.
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
January 27, 2022 8:23am EST
https://investor.todosmedical.com/news-events...-secondary
April 11, 2022 06:30 ET
"Patients in both treatment groups were allowed to receive standard of care including remdesivir, dexamethasone , anti-IL6 receptor antibodies, and JAK inhibitors. "
Almost 1/2 the people died on the big boy drugs. Guess 'that stuff' isn't all what it's cracked up to be.
"The prespecified primary endpoint was death at or before day 60. Sabizabulin treatment resulted in a clinically and statistically meaningful 55% relative reduction in deaths (p=0.0029) in the intent to treat population. Placebo group (n=52) had a 45% mortality rate compared to the sabizabulin-treated group (n=98) which had a 20% mortality rate. The secondary efficacy endpoints are still being analyzed at the time of this release."
1 out of 5 died on Sabizabulin. I didn't look to see what happened after day 60.
If sabizabulin reduced deaths 55%, then maybe Todos could have wrote the PR, Tollovid reduced deaths 100%. What is interesting in the Todos trial is those patients that received SOC and a death rate of 22% COVID-related deaths in placebo group. The SOC placebo arm has a very similar death rate to those on sabizabulin.
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
January 27, 2022 8:23am EST
https://investor.todosmedical.com/news-events...-secondary
(1)
(0)